CA3141855A1 - Composes heterocycliques en tant qu'inhibiteurs de prmt5 - Google Patents

Composes heterocycliques en tant qu'inhibiteurs de prmt5 Download PDF

Info

Publication number
CA3141855A1
CA3141855A1 CA3141855A CA3141855A CA3141855A1 CA 3141855 A1 CA3141855 A1 CA 3141855A1 CA 3141855 A CA3141855 A CA 3141855A CA 3141855 A CA3141855 A CA 3141855A CA 3141855 A1 CA3141855 A1 CA 3141855A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
pyrrolo
quinolin
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141855A
Other languages
English (en)
Inventor
Wen-Lian Wu
Zhiqiang Yang
Francis Lee
John Qiang TAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angex Pharmaceutical Inc
Original Assignee
Angex Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angex Pharmaceutical Inc filed Critical Angex Pharmaceutical Inc
Publication of CA3141855A1 publication Critical patent/CA3141855A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs hétérocycliques de PRMT5 et leurs procédés de préparation. L'invention concerne également des compositions pharmaceutiques comprenant lesdits inhibiteurs de PRMT5 et des méthodes d'utilisation de celles-ci pour le traitement du cancer, de maladies infectieuses et d'autres troubles associés à PRMT5.
CA3141855A 2019-05-30 2020-05-27 Composes heterocycliques en tant qu'inhibiteurs de prmt5 Pending CA3141855A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962854435P 2019-05-30 2019-05-30
US62/854,435 2019-05-30
US202062966337P 2020-01-27 2020-01-27
US62/966,337 2020-01-27
PCT/US2020/034711 WO2020243178A1 (fr) 2019-05-30 2020-05-27 Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Publications (1)

Publication Number Publication Date
CA3141855A1 true CA3141855A1 (fr) 2020-12-03

Family

ID=73553050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141855A Pending CA3141855A1 (fr) 2019-05-30 2020-05-27 Composes heterocycliques en tant qu'inhibiteurs de prmt5

Country Status (7)

Country Link
EP (1) EP3976038A4 (fr)
JP (1) JP2022534998A (fr)
KR (1) KR20220016194A (fr)
CN (1) CN114126614A (fr)
AU (1) AU2020283505A1 (fr)
CA (1) CA3141855A1 (fr)
WO (1) WO2020243178A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406908A (zh) * 2022-08-09 2024-02-16 大陸商上海湃隆生物科技有限公司 新型prmt5抑制劑及其應用
WO2024153128A1 (fr) * 2023-01-18 2024-07-25 Shanghai Antengene Corporation Limited Composés inhibiteurs de prmt5 et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CA2969295A1 (fr) * 2016-06-06 2017-12-06 Pfizer Inc. Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
WO2018152548A1 (fr) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
ES2885180T3 (es) * 2017-08-09 2021-12-13 Prelude Therapeutics Inc Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5)
EP3720495A4 (fr) * 2017-12-05 2021-06-02 Angex Pharmaceutical, Inc. Composés hétérocycliques en tant qu'inhibiteurs de prmt5
US11459330B2 (en) * 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
BR112021002267A8 (pt) * 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5

Also Published As

Publication number Publication date
CN114126614A (zh) 2022-03-01
KR20220016194A (ko) 2022-02-08
JP2022534998A (ja) 2022-08-04
EP3976038A4 (fr) 2023-07-12
AU2020283505A1 (en) 2021-12-23
EP3976038A1 (fr) 2022-04-06
WO2020243178A1 (fr) 2020-12-03

Similar Documents

Publication Publication Date Title
CN112368272B (zh) Shp2抑制剂及其用途
AU2018364938B2 (en) Macrocyclic compounds as TRK kinase inhibitors and uses thereof
AU2023251425A1 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
KR102460389B1 (ko) Mnk 억제제 및 그와 관련된 방법
WO2021061515A1 (fr) Inhibiteurs de shp2 et leurs utilisations
CA2778680C (fr) Derives heteroaryles contenant n en tant qu'inhibiteurs de kinase jak3
AU2018381004B2 (en) Heterocyclic compounds as PRMT5 inhibitors
JP2009531274A (ja) キナーゼ阻害性ピロロピリジン化合物
EP3638680B1 (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
CA3111380A1 (fr) Modulateurs de la monoacylglycerol lipase
KR20210145787A (ko) Prmt5를 표적으로 하는 화합물
RU2579513C2 (ru) Ингибиторы активности акт
CA3141855A1 (fr) Composes heterocycliques en tant qu'inhibiteurs de prmt5
WO2021257614A1 (fr) Inhibiteurs hétérocycliques d'enpp1
JP3463935B2 (ja) 中枢神経系障害の処置において有用な３−オキソ−ピリド（１，２−▲ａ▼）ベンズイミダゾール−４−カルボキシル及び４−オキソ−アゼピノ（１，２−▲ａ▼）ベンズイミダゾール−５−カルボキシル誘導体
CA2910759C (fr) Derives d'imidazo-triazine utilises comme inhibiteurs de la pde10
TW202045501A (zh) 雙環醚o-糖蛋白-2-乙醯胺基-2-去氧-3-d-哌喃葡萄糖苷酶抑制劑
WO2022127755A1 (fr) Composés utilisés en tant qu'inhibiteurs de la caséine kinase
CN114728976B (zh) 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
CA3215521A1 (fr) Nouveaux derives de pyrazolo[1,5-a]pyrimidine utilises en tant que ligands sigma
WO2021206955A1 (fr) Composés macrocycliques en tant qu'inhibiteurs de kinases et leurs utilisations
CN114380845A (zh) 一种并杂环类化合物，包含其的药物组合物，其制备方法及其用途
US20220089612A1 (en) Heterocyclic compounds as prmt5 inhibitors
WO2015145369A1 (fr) Procédé pour la préparation de composés d'imidazo[4,5-c]quinoline substitués, d'intermédiaires et de polymorphes de ceux-ci
CA3236550A1 (fr) Inhibiteurs de spirotricycle ripk1 et leurs procedes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211124

EEER Examination request

Effective date: 20211124

EEER Examination request

Effective date: 20211124

EEER Examination request

Effective date: 20211124

EEER Examination request

Effective date: 20211124